American Society of Hematology

Figure 2.

$Graphs of cumulative QALYs gained and life-years gained. (A) A graph of cumulative QALYs gained over a lifetime horizon in second-line CAR-T compared with SOC in primary refractory/early relapse patients. The red curve represents the base case scenario in which patients who received second-line CAR-T and are event-free at 2 years have a 6% rate of relapse from 2 to 5 years, and additional QALYs are gained throughout the cohort’s lifetime. The green curve represents the optimistic scenario in which second-line CAR-T has a low rate of relapse between 2 and 5 years, and the blue curve represents the pessimistic scenario in which second-line CAR-T has a high rate of relapse between 2 and 5 years. (B) A graph of cumulative life-years gained over a lifetime horizon in second-line CAR-T compared with SOC in primary refractory/early relapse patients. The orange curve represents the base case scenario in which patients who received second-line CAR-T and are event-free at 2 years have a 6% rate of relapse from 2 to 5 years, and additional life-years are gained, or that second-line CAR-T patients have lower mortality. The green curve represents the optimistic scenario in which second-line CAR-T has a low rate of relapse between 2 and 5 years, and the blue curve the pessimistic scenario in which second-line CAR-T has a high rate of relapse between 2 and 5 years.$

Graphs of cumulative QALYs gained and life-years gained. (A) A graph of cumulative QALYs gained over a lifetime horizon in second-line CAR-T compared with SOC in primary refractory/early relapse patients. The red curve represents the base case scenario in which patients who received second-line CAR-T and are event-free at 2 years have a 6% rate of relapse from 2 to 5 years, and additional QALYs are gained throughout the cohort’s lifetime. The green curve represents the optimistic scenario in which second-line CAR-T has a low rate of relapse between 2 and 5 years, and the blue curve represents the pessimistic scenario in which second-line CAR-T has a high rate of relapse between 2 and 5 years. (B) A graph of cumulative life-years gained over a lifetime horizon in second-line CAR-T compared with SOC in primary refractory/early relapse patients. The orange curve represents the base case scenario in which patients who received second-line CAR-T and are event-free at 2 years have a 6% rate of relapse from 2 to 5 years, and additional life-years are gained, or that second-line CAR-T patients have lower mortality. The green curve represents the optimistic scenario in which second-line CAR-T has a low rate of relapse between 2 and 5 years, and the blue curve the pessimistic scenario in which second-line CAR-T has a high rate of relapse between 2 and 5 years.

This Feature Is Available To Subscribers Only